GleamWall
中文EN

VNDA Vanda Pharmaceuticals Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1347178 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY8.1%
TTM net income YoY-226.4%
TTM EPS YoY-220.8%
Revenue 3-yr CAGR2.7%
Net income 3-yr CAGR—

Margins

Gross margin93.6%
Operating margin-77.6%
Net margin-119.9%
FCF margin-61.0%
EBITDA margin-77.1%

Returns

ROE-82.5%
ROA-55.9%
ROIC (approx.)-52.6%
Asset turnover0.47x

Leverage & solvency

Liabilities / assets47.7%
Debt / equity0.00x
Current ratio1.54x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.51x
Accruals ratio-27.6%
Payout ratio—
Capex / revenue0.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$69.81M$50.53M$51.72M$57.22M$56.26M$52.59M$50.04M$53.19M
Cost of revenue$4.15M$3.56M$3.16M$3.83M$2.95M$2.74M$3.52M$2.59M
Gross profit$65.66M$46.97M$48.56M$53.38M$53.30M$49.85M$46.52M$50.59M
R&D expense$27.62M$36.95M$28.43M$29.01M$22.56M$21.99M$35.71M$19.84M
SG&A expense$59.58M$71.84M$68.36M$62.98M$60.27M$64.62M$50.08M$39.28M
Operating income-$23.52M-$63.81M-$50.22M-$40.35M-$31.28M-$38.50M-$41.03M-$10.28M
Pretax income-$22.39M-$62.38M-$48.42M-$38.00M-$28.39M-$34.89M-$37.37M-$6.50M
Income tax$174,000$129,000$143,000$103.19M-$5.80M-$7.68M-$7.87M-$1.58M
Net income-$22.56M-$62.51M-$48.57M-$141.19M-$22.59M-$27.21M-$29.49M-$4.91M
EBITDA-$23.28M-$63.54M-$49.95M-$40.05M-$30.98M-$38.24M-$40.80M-$10.06M
EPS (basic)-0.37-1.04-0.82—-0.38-0.46-0.50—
EPS (diluted)-0.37-1.04-0.82—-0.38-0.46-0.50—
Weighted avg. shares (diluted)60.47M60.23M59.46M—59.09M58.99M58.53M—
Balance sheet
Cash & equivalents$61.93M$55.88M$54.03M$84.85M$70.02M$80.98M$111.80M$102.78M
Receivables$60.32M$59.69M$56.88M$54.58M$50.54M$44.99M$44.60M$47.10M
Inventory$1.53M$1.68M$1.70M$1.85M$2.04M$2.17M$1.92M$1.73M
Current assets$238.47M$264.48M$293.17M$347.26M$367.50M$394.92M$407.91M$438.89M
PP&E, net$3.03M$2.58M$2.25M$2.25M$2.46M$2.42M$2.44M$2.13M
Intangibles$111.13M$113.11M$115.10M$117.09M$108.84M$110.59M$112.34M$114.10M
Total assets$382.33M$412.47M$433.52M$488.95M$601.14M$624.75M$631.94M$656.20M
Current liabilities$154.98M$164.03M$135.58M$145.16M$117.87M$121.49M$103.92M$99.98M
Total liabilities$182.47M$192.28M$152.76M$161.76M$135.14M$138.42M$120.52M$117.66M
Shareholders' equity$199.86M$220.19M$280.76M$327.19M$466.00M$486.33M$511.42M$538.55M
Shares outstanding60.47M60.45M60.14M59.10M59.10M59.08M58.93M58.31M
Cash flow statement
Operating cash flow-$28.43M-$31.07M-$50.22M-$29.42M-$31.63M-$15.25M-$33.15M-$1.82M
Capital expenditure$311,000$190,000$221,000$102,000$161,000$299,000$436,000$214,000
Free cash flow-$28.75M-$31.26M-$50.44M-$29.52M-$31.79M-$15.55M-$33.58M-$2.03M
Investing cash flow$35.21M$33.81M$20.23M$44.87M$21.36M-$15.27M$43.90M$3.99M
Financing cash flow-$877,000-$856,000-$776,000-$640,000-$517,000-$425,000-$1.32M-$155,000
Depreciation & amortization$243,000$267,000$273,000$304,000$301,000$267,000$231,000$221,000
Stock-based compensation$2.34M$2.11M$2.56M$2.29M$2.11M$2.11M$2.97M$2.86M

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.